PreveCeutical Granted Approval to Acquire and Use Human Mucosal Tissue for Final Phase of Sol-Gel Program

Stock Information for PreveCeutical Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PreveCeutical Medical Inc.

PreveCeutical Announces Filing of Provisional Patent Application
PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection
PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs
PreveCeutical Issued Statement Regarding Promotional Activity
PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report
PreveCeutical Announces Certain Warrants Expiring on June 29, 2020

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.